Kinetics of circulating human IgG4 after diethylcarbamazine and ivermectin treatment of bancroftian filariasis.
Identifieur interne : 005928 ( PubMed/Corpus ); précédent : 005927; suivant : 005929Kinetics of circulating human IgG4 after diethylcarbamazine and ivermectin treatment of bancroftian filariasis.
Auteurs : C N Wamae ; J M Roberts ; M L Eberhard ; P J LammieSource :
- The Journal of infectious diseases [ 0022-1899 ] ; 1992.
English descriptors
- KwdEn :
- Animals, Diethylcarbamazine (pharmacology), Diethylcarbamazine (therapeutic use), Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (immunology), Follow-Up Studies, Humans, Immunoglobulin G (biosynthesis), Immunoglobulin G (blood), Ivermectin (pharmacology), Ivermectin (therapeutic use), Kinetics, Microfilariae (drug effects), Wuchereria bancrofti (drug effects), Wuchereria bancrofti (immunology).
- MESH :
- chemical , biosynthesis : Immunoglobulin G.
- chemical , blood : Immunoglobulin G.
- chemical , pharmacology : Diethylcarbamazine, Ivermectin.
- chemical , therapeutic use : Diethylcarbamazine, Ivermectin.
- blood : Elephantiasis, Filarial.
- drug effects : Microfilariae, Wuchereria bancrofti.
- drug therapy : Elephantiasis, Filarial.
- immunology : Elephantiasis, Filarial, Wuchereria bancrofti.
- Animals, Follow-Up Studies, Humans, Kinetics.
Abstract
Patent filarial infections are associated with elevated levels of parasite-specific IgG4. This study investigated the shifts of filarial-specific human IgG and IgG4 antibodies after diethylcarbamazine and ivermectin treatment of bancroftian filariasis. Thirty adult Haitians were treated first with a 1-mg clearing dose of ivermectin and then with either one or two 200-micrograms/kg doses of ivermectin or with 12 daily 6-mg/kg doses of diethylcarbamazine. Posttreatment levels of antifilarial IgG4 were dependent on both treatment group and time of follow-up. IgG4 increased markedly to a maximum by day 30 in all treatment groups and then began to decrease; the greatest decrease was among diethylcarbamazine-treated patients. Posttreatment microfilaremia was inversely correlated with the decrease in IgG4; thus, shifts in IgG4 were associated with treatment response for all groups. Antifilarial IgG levels were not correlated with drug treatment and did not change to the same degree as did IgG4 responses.
PubMed: 1583340
Links to Exploration step
pubmed:1583340Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Kinetics of circulating human IgG4 after diethylcarbamazine and ivermectin treatment of bancroftian filariasis.</title><author><name sortKey="Wamae, C N" sort="Wamae, C N" uniqKey="Wamae C" first="C N" last="Wamae">C N Wamae</name><affiliation><nlm:affiliation>Department of Parasitology, Tulane University, New Orleans, Louisiana.</nlm:affiliation></affiliation></author><author><name sortKey="Roberts, J M" sort="Roberts, J M" uniqKey="Roberts J" first="J M" last="Roberts">J M Roberts</name></author><author><name sortKey="Eberhard, M L" sort="Eberhard, M L" uniqKey="Eberhard M" first="M L" last="Eberhard">M L Eberhard</name></author><author><name sortKey="Lammie, P J" sort="Lammie, P J" uniqKey="Lammie P" first="P J" last="Lammie">P J Lammie</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1583340</idno><idno type="pmid">1583340</idno><idno type="wicri:Area/PubMed/Corpus">005928</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005928</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Kinetics of circulating human IgG4 after diethylcarbamazine and ivermectin treatment of bancroftian filariasis.</title><author><name sortKey="Wamae, C N" sort="Wamae, C N" uniqKey="Wamae C" first="C N" last="Wamae">C N Wamae</name><affiliation><nlm:affiliation>Department of Parasitology, Tulane University, New Orleans, Louisiana.</nlm:affiliation></affiliation></author><author><name sortKey="Roberts, J M" sort="Roberts, J M" uniqKey="Roberts J" first="J M" last="Roberts">J M Roberts</name></author><author><name sortKey="Eberhard, M L" sort="Eberhard, M L" uniqKey="Eberhard M" first="M L" last="Eberhard">M L Eberhard</name></author><author><name sortKey="Lammie, P J" sort="Lammie, P J" uniqKey="Lammie P" first="P J" last="Lammie">P J Lammie</name></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="ISSN">0022-1899</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Diethylcarbamazine (pharmacology)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (immunology)</term><term>Follow-Up Studies</term><term>Humans</term><term>Immunoglobulin G (biosynthesis)</term><term>Immunoglobulin G (blood)</term><term>Ivermectin (pharmacology)</term><term>Ivermectin (therapeutic use)</term><term>Kinetics</term><term>Microfilariae (drug effects)</term><term>Wuchereria bancrofti (drug effects)</term><term>Wuchereria bancrofti (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Microfilariae</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Follow-Up Studies</term><term>Humans</term><term>Kinetics</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patent filarial infections are associated with elevated levels of parasite-specific IgG4. This study investigated the shifts of filarial-specific human IgG and IgG4 antibodies after diethylcarbamazine and ivermectin treatment of bancroftian filariasis. Thirty adult Haitians were treated first with a 1-mg clearing dose of ivermectin and then with either one or two 200-micrograms/kg doses of ivermectin or with 12 daily 6-mg/kg doses of diethylcarbamazine. Posttreatment levels of antifilarial IgG4 were dependent on both treatment group and time of follow-up. IgG4 increased markedly to a maximum by day 30 in all treatment groups and then began to decrease; the greatest decrease was among diethylcarbamazine-treated patients. Posttreatment microfilaremia was inversely correlated with the decrease in IgG4; thus, shifts in IgG4 were associated with treatment response for all groups. Antifilarial IgG levels were not correlated with drug treatment and did not change to the same degree as did IgG4 responses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1583340</PMID><DateCreated><Year>1992</Year><Month>06</Month><Day>18</Day></DateCreated><DateCompleted><Year>1992</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1899</ISSN><JournalIssue CitedMedium="Print"><Volume>165</Volume><Issue>6</Issue><PubDate><Year>1992</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Kinetics of circulating human IgG4 after diethylcarbamazine and ivermectin treatment of bancroftian filariasis.</ArticleTitle><Pagination><MedlinePgn>1158-60</MedlinePgn></Pagination><Abstract><AbstractText>Patent filarial infections are associated with elevated levels of parasite-specific IgG4. This study investigated the shifts of filarial-specific human IgG and IgG4 antibodies after diethylcarbamazine and ivermectin treatment of bancroftian filariasis. Thirty adult Haitians were treated first with a 1-mg clearing dose of ivermectin and then with either one or two 200-micrograms/kg doses of ivermectin or with 12 daily 6-mg/kg doses of diethylcarbamazine. Posttreatment levels of antifilarial IgG4 were dependent on both treatment group and time of follow-up. IgG4 increased markedly to a maximum by day 30 in all treatment groups and then began to decrease; the greatest decrease was among diethylcarbamazine-treated patients. Posttreatment microfilaremia was inversely correlated with the decrease in IgG4; thus, shifts in IgG4 were associated with treatment response for all groups. Antifilarial IgG levels were not correlated with drug treatment and did not change to the same degree as did IgG4 responses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wamae</LastName><ForeName>C N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Parasitology, Tulane University, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Eberhard</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Lammie</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Y02-00005</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008842" MajorTopicYN="N">Microfilariae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="N">Wuchereria bancrofti</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1583340</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005928 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 005928 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:1583340
|texte= Kinetics of circulating human IgG4 after diethylcarbamazine and ivermectin treatment of bancroftian filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:1583340" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |